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Posttransplant Lymphoproliferative Disorders
(PTLD) after Allogeneic Stem Cell Transplantation
in High-Risk Patients
Nishitha Reddy,1 Katayoun Rezvani,2 A. John Barrett,3 Bipin N. Savani1Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative dis-
order (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted
SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV
reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving
allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve
the needs of the increasingly enlarging population of high-risk SCT recipients across the globe.
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B CELL LYMPHOPROLIFERATIVE DISORDER
(PTLD) AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Risk Ractor, Biology, and Pathogenesis
EBV-associated PTLD following allogeneic stem
cell transplantation (allo-SCT) is a life-threatening
complication resulting predominantly from outgrowth
of donor-derived EBV-infected B cells [1]. Most cases
of PTLD are associated with EBV infection from B-
lymphocytes, which in the setting of immunosuppres-
sion can induce a transformation to a lymphoproliferative
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6/j.bbmt.2010.08.007EBV reactivation and especially PTLD is expensive,
and treatments can also carry risk. Patients undergoing
unmanipulated allo-SCT have a risk of developing
EBV-PTLD of approximately 1%, whereas at the
other extreme, T cell depletion using antibodies spe-
cific for CD2 and CD3 was associated with very high
risk of PTLD (71%) [2]. The factor that conferred
the greatest relative risk was the use of anti-CD3
antibody to treat graft-versus-host disease (GVHD).
A recently published study evaluated 26,901 allo-
SCT recipients to define the risk factors for PTLD.
PTLD developed in 127 (0.47%) patients, with more
than 80% of cases occurring within the first year after
allo-SCT. The authors identified 4 high-risk factors
(aged $50 years at transplantation, T cell depletion
of the graft, antithymocyte globulin [ATG] use, and
unrelated or HLA-mismatched grafts) associated
with increased risk for PTLD. Patients with no risk
factors had a cumulative incidence of 0.2% versus
8.1% for patients in whom 3 or more risk factors
were present. In this study, a majority of patients
(transplant period 1964 to 1994) received matched
related donor SCT [3].
T cell depletion is a risk factor, but the risk associ-
ated with various approaches to depletion varied sub-
stantially. The use of sheep red blood cell rosetting,
anti-T or anti-T, and anti-natural killer (NK)monoclo-
nal antibodies (mAbs) was associated with relative risks
of .10-fold. The use of methods that resulted in bal-
anced loss of B cells and T cells was not associated
with significantly increased risk. The use of lectins,591
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with a statistically significant increased relative risk
[2,4,5]. It is likely that the protective effect of B cell
depletion derived from both decreased numbers of
virus-carrying donor lymphocytes and the elimination
of the target cell for transformation. In contrast to
EBV-PLPD in the solid-organ transplant setting, the
recipient’s age, EBV seronegativity, and underlying
disease are not risk factors for PTLD in allo-SCT [3,6].
Late PTLD after allo-SCT differ in their risk fac-
tors, pathology, and EBV association. These tumors
are sometimes of T cell rather than B cell origin, and at
times are not EBV associated [7,8]. Late-onset PTLD
not associated with EBV have also been described in
solid-organ transplant recipients [9]. Hodgkin lym-
phoma (HL) occurs at increased frequency following
allo-SCT generally late onset. A 6-fold increased risk
ofHL in SCT recipients in comparisonwith the general
population is similar to the increase in risk in human
immunodeficiency virus (HIV)-positive patients [10].
Despite higher T cell dose in the graft, recipients
of allo-peripheral blood stem cell transplantations
(PBSCTs) also are at risk for PTLD [11]. The median
time to the diagnosis of PTLD is similar to that for
bone marrow transplant (BMT) recipients. T cell de-
pletion of the PBSC product and underlying diagnosis
of immune deficiency in the recipient were identified as
risk factors in multivariate analysis. Reduced intensity
conditioning (RIC) transplants have also been associ-
ated with EBV-PTLD [12,13]. Fludarabine alone has
also been reported to be associated with the
development of EBV-PTLD [14], so the contribution
of transplantation to the problem is not yet clear. Be-
cause EBV does not cross the blood-placenta barrier,
risk after cord blood transplantation (CBT) might be
anticipated to be lower than other donor sources. Al-
ternately, CBT recipients are anticipated to have a
higher incidence of PTLD because they resemble
T cell-depleted SCT as they lack EBV-specific cyto-
toxic T cells. As the incidence of EBV-PTLD in
CBT recipients appears not to differ from that in recip-
ients of unmanipulated BM grafts, it may be that these
factors balance out [15,16]. High incidence was
reported in an RIC CBT recipients study, expected
to be related to use of antithymocyte globulin (ATG)
in the conditioning regimen [16].
The cellular responses to classes of EBV antigen
(especially latent versus lytic) and to particular anti-
gens are well recognized [17-19]. Thus, different
peptide epitopes elicit different magnitudes of T cell
response. Evidence has been presented suggesting
a relationship between EBV CD81 T cell frequencies
and viral load in peripheral blood mononuclear cells
(PBMC). Whereas EBV reactivation as evidenced by
elevated EBV viral loads was not highly predictive of
the development of EBV-PTLD, it is impaired EBV
specific T cell recovery in conjunction with elevatedEBV viral load that was associated with development
of EBV-PTLD in all 5 reported cases [20]. Progressive
loss of EBV-specific CD41 and CD81 T cells has also
been associated with high risk for developing EBV-
associated lymphomas in acquired immune deficiency
syndrome patients [21]. However, the relative impor-
tance ofCD81 andCD41 responses, responses to latent
versus lytic viral antigens expressed on tumor cells, or
responses to specific individual viral antigens remains
to be determined. Several investigators have presented
evidence for a critical role of CD41 T cells. These
may exert direct cytotoxic effects or suppress the
outgrowth of EBV-transformed B cell lines [12,22].EBV-PTLD after auto-SCT
Autologous BMT or peripheral blood progenitor
cell (PBPC) transplantation has also been associated
with EBV-PTLD, although much less frequently than
after allo-SCT. T cell depletion (for the removal of
T cell tumor cells) appears to be the major risk factor,
but EBV-PTLD has also occurred in association with
CD34 cell selection [23-26]. The major determinants
of the risk period for PTLD are presumed to be
immunologic, and several investigators have presented
evidence that reconstitution of CD81 T cell immunity
to EBV generally occurs during the 6-month period
following allo-SCT. It may occur even more rapidly
following autologous PBPC transplantation.Clinical Presentation and Diagnosis
Fever, generalized lymphadenopathy, respiratory
compromise, and rising liver transaminase levels are
typical and have usually been associated with a rapidly
progressive multiorgan failure and death. Lesions are
nodal and extra-nodal, frequently involving Wal-
deyer’s ring, the gastrointestinal tract, the liver, and
the central nervous system. Tumors that arise later
after transplantation (.1 year) are more commonly
localized and often have an indolent course. On the
contrary, patients with EBV infection usually asymp-
tomatic initially. As PTLD may evolve progressively
from an EBV-reactivation (infection) to polyclonal
disorder to a more aggressive monoclonal variant
PTLD, early diagnosis is an important so that preemp-
tive therapy can be started early in the course. Mea-
surement of EBV-DNA viral load by quantitative
PCR amplification assays can be a sensitive aid to early
diagnosis, but it is not always specific for disease onset.
Different assays use whole blood, serum, or PBMC
and require differing interpretation. When PBMC
are assayed, an elevated EBV-DNA may reflect both
EBV in normal B cells (a population that may be ex-
panded in immunosuppressed patients) and EBV in
transformed cells. Assays of EBV in serum reflect virus
shedding, which occurs intermittently in normal
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lytically transformed B cells as well as virus released
from necrotic transformed cells. Assays measuring
whole blood will measure EBV-DNA from all these
sources. In general, assays using PBMC are the most
sensitive; but in all assays, elevated loads may not
always reflect PTLD.
The definitive diagnosis of PLTD requires biopsy
with in situ hybridization or immunochemistry to de-
fine viral association. EBV-encoded RNA in situ hy-
bridization is the most sensitive tool for detecting
virus in tumor. LMP-1 staining is also available in
most pathology laboratories but is negative in the
subset of tumors that do not express the viral antigen.
Immunohistochemistry for EBNA-1 could also be
broadly applicable.
PTLD includes a heterogeneous group of lym-
phoproliferative disorders ranging from reactive,
polyclonal hyperplasia to aggressive non-Hodgkin
lymphomas. A revised classification was published in
2008 by the World Health Organization and recom-
mends classifying PTLD into 4 categories: (1) early
lesions, (2) polymorphic PTLD, (3) monomorphic
PTLD, and (4) classic HL-type PTLD [27]. All types
are associated with EBV. There is no consensus on the
prognostic predictive value of either morphology or
clonality. However, it is clear that, on occasions,
patients with polyclonal disease may progress despite
aggressive therapy including DLI [28]. Whereas in
solid organ transplant recipients, PTLD most com-
monly arises in host B cells, in allo-SCT recipients
EBV-PTLD usually arises in donor B-lymphocytes
(exceptions auto-SCT or auto recovery).
Earlier studies in recipients of allo-SCT that were
selectively T cell-depleted to prevent GVHD, suggest-
ing that an elevated EBV-DNA load was highly pre-
dictive of EBV-PTLD [20,29,30]. Follow-up studies,
however, which also included non-T cell-depleted
allo-SCT recipients, showed that small population of
patients with elevated EBV-DNA subsequently devel-
oped PTLD [1,17,31-33]. Recent evidence-based
review guidelines from the European Conference in
Infections in Leukemia recommend weekly screening
of EBV-DNA for at least 3 months in high-risk allo-
SCT recipients [31]. Serial monitoring is important
to distinguish patients with a stable-elevated EBV-
DNA load from those with increasing EBV-DNA,
which may indicate preemptive therapy with (eg,
rituximab) to prevent developing PTLD. Combined
monitoring of EBV-DNA and EBV-specific CTL re-
sponses appears to better predict individual patients at
risk for PTLD development [20,28]. Unfortunately,
EBV-specific CTL assay is not routinely available
commercially and available mainly in the research set-
ting. The context and risk factors are also important in
deciding when to intervene; preemptive intervention
in high risk early post-allo-SCT recipients is preferred(eg, older adults who received URD allo-SCT with
severe GVHD who have received in vivo or ex vivo
T cell depletion).EBV Reactivation and PTLD Rates Are
Expected to Increase
At present, 15,000-20,000 patients receive allo-
SCT annually throughout the world, and more than
half of all allo-SCT are performed from nonmatched
related donor (MRD) stem cell sources [34].With con-
tinued improvement in SCT outcome, the indications
for SCT continue to grow. Furthermore, the sourced
of donor stem cell and the number of suitable matches
are expanding. At the same time, modified transplanta-
tion regimens have facilitated safer procedures despite
an increase in patient’s age and comorbidies. An aging
population is increasing the proportion of individuals
susceptible to diseases for which SCT is indicated.
Moreover, proposed national health insurance reforms
in theUnited States may expand the number of insured
patients and reduce economic barriers for allo-SCT in
more patients [35-38]. Because EBV reactivation and
PTLD risk is reported to be high among CBT,
mismatched (MM), and unrelated donor (URD) allo-
SCT, and as most centers use ATG with URD SCT,
more high-risk patients will receive an allo-SCT every
year and cumulative numbers of patients with EBV-
reactivation and PTLD are likely to rise [3,16,39,40].Current Therapeutic Options to Control EBV
Reactivation and PTLD
Reduced immunosuppression
Reducing immunosuppression (IS) to restore
immune responses to EBV is not usually a useful ap-
proach for treating PTLD early after allo-SCT because
the patients are profoundly immunosuppressed and the
regenerating immune system cannot recover rapidly
enough to eradicate the lymphoproliferative process
[17,31]. Although data is limited as to the safety and
efficacy of this approach in treating PTLD and there
is a rational fear that reducing IS will induce or
exacerbate GVHD and/or EBV replication, careful
modulation and reduction of IS has been successfully
used early post-SCT in select cases to prevent PTLD
at the time of EBV reactivation [41].
EBV-specific cytotoxic T cell line (CTL)
The problem of alloreactivity can also be overcome
by infusing EBV-specific cytotoxic T cell lines (CTLs)
generated using EBV-transformed lymphoblastoid B
cell lines (EBV-LCL) which, as professional antigen-
presenting cells (APCs), efficiently present the viral
antigens. Because of the underlying latency of EBV
and the highly immunogenic nature of EBV disease,
adoptive transfer of EBV-CTL is extremely effective
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PTLD is increasing in the clinic and a large quantity of
recent basic science literature investigating the ideal
approach has been recently reported. There are
number of different approaches to develop EBV-
specific CTL, for example, using EBNA-1-specific
T cells or peptide-selected T cells [19,47]. Also,
there are preclinical studies using CD81CTL cells
or CD41 cytotoxic T cells, or both [48-50].
The adoptive immunotherapy is reported to be
highly effective as prophylaxis in high-risk patients
with a past history of PTLD or patients receiving
selective T cell depletion [51,52]. However, several of
these approaches remain experimental and additional
drawbacks are the time and facilities required for CTL
production. Another strategy is to develop a bank of
partially HLA-matched allogeneic lines, which can be
readily and rapidly available [53,54]. However, limited
numbers of stem cell allograft recipients have been
treated in this way, and further studies are needed
before unrelated EBV-specific CTLs can be widely
offered and available to all allo-SCT recipients.Anti-CD20 mAb
Rituximab has been used as prophylaxis (preemptive
therapy for EBV-reactivation after allo-SCT) and treat-
ment for PTLD after allo-SCT, with initial response
rates between 55% and 100% in small case series
[1,17,31,32,55,56]. Because CD20 expression is not
confined to malignant cells, normal B cells are also
destroyed. This can be a significant concern in patients
who are already immunosuppressed, and fatal viral
infections have been reported after rituximab therapy
[57]. Rituximab can deplete B cells (both donor and
host) for 6 to 9 months in these already immunosup-
pressed patients [58,59]. An additional concern is
that when used as therapy, it does not restore the
cellular immune response to EBV, which is a crucial
requirement if EBV-mediated B cell proliferation is to
be controlled long term [60]. Additionally, anti-CD20
antibodies are poorly effective against CNS disease be-
cause of low penetrance across the blood-brain barrier.
Antiviral therapy
The limited data available on antiviral therapy in
patients with EBV reactivation and PTLD following
allo-SCT does not support their use. Long-term pro-
phylaxis with antiviral agents or IVIG may decrease
the incidence of EBV reactivation and PTLD by lim-
iting intercellular virus transmission [61], but EBV
reactivation continues to be reported in high-risk
transplants such as CBT or URD, despite long-term
antiviral prophylaxis with or without IVIG in the first
100 days or longer posttransplantation. The main
cause of PTLD is the proliferation of the latently in-
fected EBV1 B cells (and not lytic replication), whichis why antiviral pharmacotherapy is not expected to be
effective in this setting.
Chemotherapy
Treatment of PTLDwith chemotherapy appears to
be rarely effective, and carries the risk of further IS. One
concern is that PTLDpatients may be more susceptible
to chemotherapy toxicity after allo-SCTs following in-
tensive conditioning. There are insufficient reports sup-
porting chemotherapy for PTLD following an allo-
SCT in the immediate posttransplant setting.Time to Explore Novel But Easily Available
Strategies to Prevent EBV Reactivation Early
Posttransplantation
The highest risk of developing PTLD is during the
first 6months following a transplant. Similarly, EBV re-
activation also occurs very early posttransplant at a me-
dian interval of 45 to 51 days in 25% to 50% of patients
[1,3,62-64]. EBV reactivation leads to development of
PTLD in some patients. Removing EBV-infected
memory B cells or EBV-transformed B cells early
posttransplant might prevent EBV reactivation and
therefore PTLD.
We hypothesized that incorporating agents that
can remove memory B cells or EBV transformed
B cells with conditioning regimen would significantly
reduce or prevent the EBV reactivation and PTLD.
Rituximab use in the peritransplant period
After autologous SCT, there is a significant defi-
ciency of CD 271 memory B cells for up to 2 years
after a single-dose rituximab [65]. Rituximab has
been evaluated as preemptive therapy in patients with
a rising EBV viral load [1,17,56]. However, use of
rituximab posttransplant risks delaying recovery of
a donor-derived B cell immune response. Rituximab
therapy 2 months after allo-SCT prevents donor
B cell reconstitution up to 1 year following HCT
[58,59]. The half-life of rituximab, despite the influ-
ence of the tumor burden, could range from several
days to months. However, if rituximab is used during
the conditioning regimen, it should theoretically
have less of an impact on donor derived B cell reconsti-
tution compared to posttransplantation administra-
tion for EBV reactivation or PTLD where effects are
long lasting. When patients received rituximab before
(within 6months of) allo-SCT for B cell lymphoid ma-
lignancies (n 5 38), we observed no EBV reactivation
reported even in patients with 3 risk factors for PTLD
(including CBT recipients) and no increased infection
[66]. In a another study, the EuropeanGroup for Blood
and Marrow Transplantation (EBMT)Working Party
on Severe Aplastic Anemia (SAA) added rituximab
on day 5 of their fludarabine, cyclophosphamide,
low-dose total body irradiation (TBI), and ATG
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in acquired SAA [67]. Vianna et al. [68] recently re-
ported no cases of PTLD following a single dose of rit-
uximab (150 mg/m2), in a cohort receiving intensive IS
including rabbit ATG (10 mg/kg) and 6 months of
methylprednisone and tacrolimus for patients receiv-
ing multivisceral transplantation (n 5 29). Rejection
was treated with an increase in the baseline tacrolimus
levels combined with 1 to 3 doses of intravenous meth-
ylprednisone (500 mg), depending on initial severity of
the rejection episode and clinical response to treatment.
For steroid resistant rejection, patients were dosed with
additional thymoglobulin or with Campath. In this
study, 13 patients (48%) experienced 19 episodes of
acute rejection, 8 (30%) episodes occurred in the first
90 days posttransplant. Despite intense IS early post-
graft, no patient developed PTLD; higher prevalence
of EBV reactivation and PTLD expected after multi-
visceral transplantation. In almost 4 years since the ini-
tiation of their intestinal transplant program, the
authors did not document a single case of PTLD.
A studyhas shown low-dose subcutaneous rituximab
effectively depletes low burdens of CD20-positive
B cells [69], a situation comparable to most SCT recip-
ients (excluding some with B cell malignancies) at the
time of conditioning.
Moreover, in patients treated with rituximab close
to the time of transplantation or given as a part of the
conditioning regimen, the additional depletion of do-
nor B cells in the stem cell graft may result in greater
protection from aGVHD (aGVHD) [70-72].
Sirolimus—a dual role as a GVHD prophylaxis
and prevention of EBV reactivation
Sirolimus (rapamycin), a macrolide antifungal an-
tibiotic isolated from Streptomyces hygroscopicus,
has potent immunosuppressive properties. Besides its
inhibitory effects on normal cells of the immune sys-
tem, rapamycin also inhibits proliferation of trans-
formed cell lines. Experimental studies suggest that
rapamycin inhibits growth of human Epstein-Barr
virus-transformed B lymphocytes [73,74]. The drug
had a profound inhibitory effect on the growth of
PTLD-like EBV 1 B cells xenotransplanted into
severe combined immunodeficiency (SCID) mice. In
this in vivo xenotransplant model, rapamycinmarkedly
delayed growth and induced regression of the estab-
lished tumors. Cell death induced by rapamycin in
BKS-2 lymphoma was found to be via apoptosis induc-
tion [73-75]. Rapamycin has been shown to be effective
in GVHD prophylaxis after SCT [76]. However, the
prevalence of PTLD following sirolimus use has not
been reported. A recent report describes 2 patients
with PTLD successfully treated with rituximab and
rapamycin after renal transplantation [77]. Similarly,
in pediatric transplant patients in whom the immuno-
suppressive therapy was converted to sirolimus, PTLDremained in remission for as long as 23months [78,79].
Another benefit is that mTOR inhibitors are effective
against a number of malignancies and they may also
add antitumor activity that could be helpful in
eliminating any residual disease post-SCT in certain
settings [80].
Implications for EBV PTLD Prevention
We propose that elimination of host and donor
memory B cells by low-dose rituximab in the condi-
tioning regimen could reduce the incidence of EBV
reactivation and PTLD post-SCT. Furthermore, rit-
uximab may attenuate donor T cell activation in the
early phase of transplantation via depletion of host B
cells and reduce the risk of aGVHD. In addition, ritux-
imab might help in vivo tumor depletion in patients
with minimal residual disease present pretransplanta-
tion. Similarly sirolimus, an effective GVHD prophy-
lactic agent, by reducing EBV transformed B cells will
reduce EBV reactivation and therefore PTLD. Com-
bining rituximab low-dose (100-150 mg/m2) and
sirolimus GVHD prophylaxis (with other immuno-
suppressive agents) might significantly reduce the
expense, morbidity, and mortality associated with
EBV-reactivation and PTLD in high-risk populations,
especially older patients receiving unrelated or mis-
matched T-depleted (in vivo or vitro) allo-SCT. The
optimal dose of rituximab during conditioning regi-
men to induce maximum benefit and prevent EBV
reactivation remains to be determined, but a single
low dose with conditioning regimen appears attractive.ACKNOWLEDGMENTS
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